534 related articles for article (PubMed ID: 11593427)
21. Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.
Wang Y; Liu J; Wu Y; Luo W; Lin SH; Lin H; Hawk N; Sun T; Guo JQ; Estrov Z; Talpaz M; Champlin R; Arlinghaus RB
Cancer Res; 2001 Jan; 61(1):138-44. PubMed ID: 11196151
[TBL] [Abstract][Full Text] [Related]
22. The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.
Yamamoto M; Kurosu T; Kakihana K; Mizuchi D; Miura O
Biochem Biophys Res Commun; 2004 Jul; 319(4):1272-5. PubMed ID: 15194504
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
[TBL] [Abstract][Full Text] [Related]
25. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
26. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
[TBL] [Abstract][Full Text] [Related]
27. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
[TBL] [Abstract][Full Text] [Related]
28. Growth hormone receptor cytoplasmic domain differentially promotes tyrosine phosphorylation of signal transducers and activators of transcription 5b and 3 by activated JAK2 kinase.
Yi W; Kim SO; Jiang J; Park SH; Kraft AS; Waxman DJ; Frank SJ
Mol Endocrinol; 1996 Nov; 10(11):1425-43. PubMed ID: 8923468
[TBL] [Abstract][Full Text] [Related]
29. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
[TBL] [Abstract][Full Text] [Related]
31. Modulation of Janus kinase 2 by p53 in ovarian cancer cells.
Reid T; Jin X; Song H; Tang HJ; Reynolds RK; Lin J
Biochem Biophys Res Commun; 2004 Aug; 321(2):441-7. PubMed ID: 15358195
[TBL] [Abstract][Full Text] [Related]
32. The c-Fes protein-tyrosine kinase suppresses cytokine-independent outgrowth of myeloid leukemia cells induced by Bcr-Abl.
Lionberger JM; Smithgall TE
Cancer Res; 2000 Feb; 60(4):1097-103. PubMed ID: 10706130
[TBL] [Abstract][Full Text] [Related]
33. Differential binding to and regulation of JAK2 by the SH2 domain and N-terminal region of SH2-bbeta.
Rui L; Gunter DR; Herrington J; Carter-Su C
Mol Cell Biol; 2000 May; 20(9):3168-77. PubMed ID: 10757801
[TBL] [Abstract][Full Text] [Related]
34. Activation of STAT5-dependent transcription by the neurotrophin receptor Trk.
Klein M; Hempstead BL; Teng KK
J Neurobiol; 2005 May; 63(2):159-71. PubMed ID: 15702476
[TBL] [Abstract][Full Text] [Related]
35. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
36. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.
Klejman A; Schreiner SJ; Nieborowska-Skorska M; Slupianek A; Wilson M; Smithgall TE; Skorski T
EMBO J; 2002 Nov; 21(21):5766-74. PubMed ID: 12411494
[TBL] [Abstract][Full Text] [Related]
37. Potential role of bcr-abl in the activation of JAK1 kinase.
Henderson YC; Guo XY; Greenberger J; Deisseroth AB
Clin Cancer Res; 1997 Feb; 3(2):145-9. PubMed ID: 9815665
[TBL] [Abstract][Full Text] [Related]
38. Establishment and phenotypic characterization of human U937 cells with inducible P210 BCR/ABL expression reveals upregulation of CEACAM1 (CD66a).
Håkansson P; Lassen C; Olofsson T; Baldetorp B; Karlsson A; Gullberg U; Fioretos T
Leukemia; 2004 Mar; 18(3):538-47. PubMed ID: 14712293
[TBL] [Abstract][Full Text] [Related]
39. Janus kinase 2: a critical target in chronic myelogenous leukemia.
Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
[TBL] [Abstract][Full Text] [Related]
40. STAT5A interacts with and is phosphorylated upon activation of the mu-opioid receptor.
Mazarakou G; Georgoussi Z
J Neurochem; 2005 May; 93(4):918-31. PubMed ID: 15857395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]